CXCL12 and neoplasm: Tumor cells release soluble factors that activate or modify monocytes in the TME to promote the polarization of Tc17 cells; IL-17 derived from Tc17 cells induces tumor cells to produce the chemokine CXCL12, thereby recruiting MDSCs to inhibit cytotoxic CD8+ T cells (56).